Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (41-50 of 324) with videos related to

Pageof 33
Sort By:
Antiviral Therapy|November 3, 2010
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patientsDamien V Cordery, Karl Hesse, Janaki Amin, et al.
AIDS (London, England)|November 2, 2013
Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic personsCaroline A Sabin, David A Cooper, Simon Collins, et al.
AIDS (London, England)|April 11, 2006
Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosisMark A Boyd, David M Burger, Praphan Phanuphak, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individualsAlan Winston, Janaki Amin, Gill Hales, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 2, 2022
Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivoAnnabelle Biscans, Socheata Ly, Nicholas McHugh, et al.
Lancet (London, England)|August 5, 2008
Lessons from a multicentre paediatric HIV trialJintanat Ananworanich, Thanyawee Puthanakit, Vonthanak Saphonn, et al.
The Journal of Clinical Endocrinology and Metabolism|March 10, 2005
Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six casesKatherine Samaras, Sarah Pett, Andrew Gowers, et al.
Journal of Chemical Theory and Computation|January 13, 2025
Ligand Reorganization for End-Point Binding Free Energy Calculations: Identifying Preferred Poses of Fentanyls in the μ Opioid ReceptorDavid D L Minh, David A Cooper, Bing Xie, et al.
Plos Computational Biology|April 5, 2013
Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug actionJames B Gilmore, Anthony D Kelleher, David A Cooper, et al.
AIDS (London, England)|November 21, 2002
Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1Sarah L Pett, Greg J Dore, Robert J Fielden, et al.
Pageof 33

Showing results (41-50 of 324) with videos related to

Sort By:
Pageof 33
Antiviral Therapy|November 3, 2010
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patientsDamien V Cordery, Karl Hesse, Janaki Amin, et al.
AIDS (London, England)|November 2, 2013
Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic personsCaroline A Sabin, David A Cooper, Simon Collins, et al.
AIDS (London, England)|April 11, 2006
Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosisMark A Boyd, David M Burger, Praphan Phanuphak, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individualsAlan Winston, Janaki Amin, Gill Hales, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 2, 2022
Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivoAnnabelle Biscans, Socheata Ly, Nicholas McHugh, et al.
Lancet (London, England)|August 5, 2008
Lessons from a multicentre paediatric HIV trialJintanat Ananworanich, Thanyawee Puthanakit, Vonthanak Saphonn, et al.
The Journal of Clinical Endocrinology and Metabolism|March 10, 2005
Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six casesKatherine Samaras, Sarah Pett, Andrew Gowers, et al.
Journal of Chemical Theory and Computation|January 13, 2025
Ligand Reorganization for End-Point Binding Free Energy Calculations: Identifying Preferred Poses of Fentanyls in the μ Opioid ReceptorDavid D L Minh, David A Cooper, Bing Xie, et al.
Plos Computational Biology|April 5, 2013
Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug actionJames B Gilmore, Anthony D Kelleher, David A Cooper, et al.
AIDS (London, England)|November 21, 2002
Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1Sarah L Pett, Greg J Dore, Robert J Fielden, et al.
Pageof 33